-
Optimization of a flow cytometry test for routine monitoring of B cell maturation antigen targeted CAR in peripheral blood Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2024-02-29 Won‐Ho Lee, Charlotte E. Graham, Hadley R. Wiggin, Hannah K. Nolan, Kiana J. Graham, Felix Korell, Mark B. Leick, Alexis L. Barselau, Estelle Emmanuel‐Alejandro, Michael A. Trailor, Juliane M. Gildea, Frederic Preffer, Matthew J. Frigault, Marcela V. Maus, Kathleen M. E. Gallagher
Chimeric antigen receptor (CAR) modified T cell therapies targeting BCMA have displayed impressive activity in the treatment of multiple myeloma. There are currently two FDA licensed products, ciltacabtagene autoleucel and idecabtagene vicleucel, for treating relapsed and refractory disease. Although correlative analyses performed by product manufacturers have been reported in clinical trials, there
-
MAGIC‐DR: An interpretable machine‐learning guided approach for acute myeloid leukemia measurable residual disease analysis Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2024-02-28 Kevin Shopsowitz, Jack Lofroth, Geoffrey Chan, Jubin Kim, Makhan Rana, Ryan Brinkman, Andrew Weng, Nadia Medvedev, Xuehai Wang
Multiparameter flow cytometry is widely used for acute myeloid leukemia minimal residual disease testing (AML MRD) but is time consuming and demands substantial expertise. Machine learning offers potential advancements in accuracy and efficiency, but has yet to be widely adopted for this application. To explore this, we trained single cell XGBoost classifiers from 98 diagnostic AML cell populations
-
Recommendations for using artificial intelligence in clinical flow cytometry Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2024-02-26 David P. Ng, Paul D. Simonson, Attila Tarnok, Fabienne Lucas, Wolfgang Kern, Nina Rolf, Goce Bogdanoski, Cherie Green, Ryan R. Brinkman, Kamila Czechowska
Flow cytometry is a key clinical tool in the diagnosis of many hematologic malignancies and traditionally requires close inspection of digital data by hematopathologists with expert domain knowledge. Advances in artificial intelligence (AI) are transferable to flow cytometry and have the potential to improve efficiency and prioritization of cases, reduce errors, and highlight fundamental, previously
-
Translating the regulatory landscape of medical devices to create fit-for-purpose artificial intelligence (AI) cytometry solutions Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2024-02-23 Goce Bogdanoski, Fabienne Lucas, Wolfgang Kern, Kamila Czechowska
The implementation of medical software and artificial intelligence (AI) algorithms into routine clinical cytometry diagnostic practice requires a thorough understanding of regulatory requirements and challenges throughout the cytometry software product lifecycle. To provide cytometry software developers, computational scientists, researchers, industry professionals, and diagnostic physicians/pathologists
-
-
Issue highlights—February 2024 Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2024-02-23 Virginia Litwin
It is a pleasure to usher in the first issue of Cytometry Part B: Clinical Cytometry for the New Year. I would like to take this opportunity to wish the International Society for Clinical Cytometry, the European Society for Clinical Cell Analyses, and Cytometry Part B, continued success in 2024. Also, I would like to thank all the people who make each issue of our journal possible, the submitting authors
-
Enhancing HLA-B27 antigen detection: Leveraging machine learning algorithms for flow cytometric analysis Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2024-02-12 Sándor Baráth, Parvind Singh, Zsuzsanna Hevessy, Anikó Ujfalusi, Zoltán Mezei, Mária Balogh, Marianna Száraz Széles, János Kappelmayer
As the association of human leukocyte antigen B27 (HLA-B27) with spondylarthropathies is widely known, HLA-B27 antigen expression is frequently identified using flow cytometric or other techniques. Because of the possibility of cross-reaction with off target antigens, such as HLA-B7, each flow cytometric technique applies a “gray zone” reserved for equivocal findings. Our aim was to use machine learning
-
Flow cytometry of DNMT1 as a biomarker of hypomethylating therapies Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2024-02-12 Philip G. Woost, Basem M. William, Brenda W. Cooper, Masumi Ueda Oshima, Folashade Otegbeye, Marcos J. De Lima, David Wald, Reda Z. Mahfouz, Yogen Saunthararajah, Tammy Stefan, James W. Jacobberger
The 5-azacytidine (AZA) and decitabine (DEC) are noncytotoxic, differentiation-inducing therapies approved for treatment of myelodysplastic syndrome, acute myeloid leukemias (AML), and under evaluation as maintenance therapy for AML postallogeneic hematopoietic stem cell transplant and to treat hemoglobinapathies. Malignant cell cytoreduction is thought to occur by S-phase specific depletion of the
-
Role of flow cytometric immunophenotyping in the diagnosis of breast implant-associated anaplastic large cell lymphoma: A 6-year, single-institution experience Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2024-01-31 Alexander Chan, Romany Auclair, Qi Gao, Paola Ghione, Steven Horwitz, Ahmet Dogan, Mikhail Roshal, Oscar Lin
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon mature T-cell neoplasm occurring in patients with textured breast implants, typically after 7–10 years of exposure. Although cytopathologic or histopathologic assessment is considered the gold standard diagnostic method for BIA-ALCL, flow cytometry (FC)-based immunophenotyping is recommended as an adjunct test. However
-
ROR1 expression in mature B lymphoid neoplasms by flow cytometry Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2024-01-25 Flávia Arandas de Sousa, Nádila Magalhães Millan, Rodolfo Patussi Correia, Andressa da Costa Vaz, Daniela Schimidell, Priscila Carmona Miyamoto, Marilia Sandoval Passaro, Bruna Garcia Nogueira, Elizabeth Xisto Souto, Nydia Strachman Bacal, Laiz Camerão Bento
Immunophenotyping by flow cytometry is an integral part of the diagnosis and classification of leukemias/lymphomas. The expression of ROR1 associated with chronic B lymphocytic leukemia (CLL) is well described in the literature, both in its diagnosis and in the follow-up of minimal residual disease (MRD) research, however, there are few studies regarding the expression pattern of ROR1 in other subtypes
-
Deciphering stage 0 hematogones by flow cytometry in follow-up bone marrow samples of pediatric B—Acute lymphoblastic leukemia cases: A potential mimicker of residual disease after anti CD19 therapy Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2024-01-19 Thulasi Raman Ramalingam, Lakshman Vaidhyanathan, Anurekha Muthu, Venkateswaran Vellaichamy Swaminathan, Ramya Uppuluri, Revathi Raj
CD19 is frequently targeted for immunotherapy in B cell malignancies, which may result in loss of CD19 expression in leukemic cells as an escape mechanism. Stage 0 hematogones (Hgs) are normal CD19-negative very early B cell precursors that can be potentially mistaken for CD19 negative residual leukemic cells by flow cytometry (FCM) in B cell acute lymphoblastic leukemia (BCP-ALL) cases treated with
-
Standardization of flow cytometric detection of antigen expression Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2024-01-12 Linhua Tian, Aaron R. Nelson, Tyler Lowe, Linda Weaver, Constance Yuan, Hao-Wei Wang, Paul DeRose, Maryalice Stetler-Stevenson, Lili Wang
Since response to antigen-based immunotherapy relies upon the level of tumor antigen expression we developed an antigen quantification assay using ABC values. Antigen quantification as a clinical assay requires methods for quality control and for interlaboratory and inter-cytometer platform standardization. A single lot of Cytotrol™ Lyophilized Control Cells (Beckman Coulter) used for all studies.
-
Issue highlights—November 2023 Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2023-12-18 Alberto Orfao
Alberto Orfao
-
Editorial on IVD cellular assay validation Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2023-12-15 Bruce H. Davis
The article in this issue of Cytometry B on “Standardization of Flow Cytometric Detection of Antigen Expression” by the NCI clinical cytometry group formerly headed by Maryalice Stetler-Stevenson and the NIST group headed by Lili Wang is deserving of not only an accompanying editorial, but special attention by all those readers intending to work in clinical cytometry for the coming decade, as it describes
-
Immunophenotypic portrait of leukemia-associated-phenotype markers in B acute lymphoblastic leukemia Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2023-11-30 Emilia Boris, Alexandre Theron, Valentin Montagnon, Nicolas Rouquier, Marion Almeras, Jérôme Moreaux, Caroline Bret
Multiparametric flow cytometry (MFC) is an essential diagnostic tool in B acute lymphoblastic leukemia (B ALL) to determine the B-lineage affiliation of the blast population and to define their complete immunophenotypic profile. Most MFC strategies used in routine laboratories include leukemia-associated phenotype (LAP) markers, whose expression profiles can be difficult to interpret. The aim of our
-
An alternative processing approach to increase CD138 intensity in flow cytometric analysis of plasma cells Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2023-11-27 Deepak Kumar, F. N. U. Kiran, Amanda Wheeler, Rory Dellamano, Richard D. Hammer
Surface median immunofluorescence intensity (MFI) of plasma cells antigens, particularly CD138, by flow cytometry underestimates plasma cell populations when compared with that estimated by morphological assessment on Wright's-stained slides. CD138 MFI using traditional sample preparation methods for flow cytometric analysis is often dim and difficult to interpret due to multiple factors. This becomes
-
CD5-negative chronic lymphocytic leukemia: Does this entity really exist? Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2023-11-28 Daniel Mazza Matos
-
Integration of T-cell clonality screening using TRBC-1 in lymphoma suspect samples by flow cytometry Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2023-11-27 Felipe Castillo, Constanza Morales, Biserka Spralja, Joaquín Díaz-Schmidt, Mirentxu Iruretagoyena, Daniel Ernst
The diagnosis of T-cell non-Hodgkin lymphomas (NHL) is challenging. The development of a monoclonal antibody specific for T-cell receptor β constant region 1 (TRBC1) provides an alternative to discriminate clonal T cells. The aim of this study was to evaluate the diagnostic potential of an anti-TRBC1 mAb for the identification of T-NHL.
-
Phenotype and oxidative burst of low-density neutrophil subpopulations are altered in common variable immunodeficiency patients Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2023-11-23 Peter Slanina, Julie Stichova, Veronika Bosakova, Iva Staniczkova Zambo, Marcela Hortova Kohoutkova, Petra Laznickova, Zita Chovancova, Jiri Litzman, Terezie Plucarova, Jan Fric, Marcela Vlkova
Common variable immunodeficiency disorder (CVID) is the most common form of primary antibody immunodeficiency. Due to low antibody levels, CVID patients receive intravenous or subcutaneous immunoglobulin replacement therapy as treatment. CVID is associated with the chronic activation of granulocytes, including an increased percentage of low-density neutrophils (LDNs). In this study, we examined changes
-
BCR::ABL1 fusion gene positive de novo acute myeloid leukemia with coexistence of NRAS mutation and presented with a peculiar CD58 positive immunophenotype. Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2023-11-15 Xueya Zhang,Xizhe Guo
-
IgE-mediated bleomycin hypersensitivity: Evidence from drug-reactive T lymphocytes. Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2023-11-15 Didier Ebo,Michiel Beyens,Alessandro Toscano,Christel Mertens,Jessy Elst,Vito Sabato
-
Flow cytometric analysis of CD34+CD38− cells; cell frequency and immunophenotype based on CD45RA expression pattern Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2023-11-06 Shumpei Mizuta, Makoto Iwasaki, Noriko Bandai, Saya Yoshida, Asami Watanabe, Hiroshi Takashima, Takeshi Ueshimo, Kazuhiro Bandai, Kensuke Fujiwara, Naoko Hiranuma, Yusuke Koba, Takahito Kawata, Akira Tamekane, Mitsumasa Watanabe
The CD34+CD38− population in bone marrow includes hematopoietic stem/progenitor cells. Recently, in acute myeloid leukemia, the focus has shifted to flow cytometry analysis targeting CD34+CD38− leukemic cells due to their effectiveness in minimal/measurable residual disease detection and prognosis prediction. Nevertheless, the immunophenotype and cell frequency of these cells in the bone marrow, in
-
Issue highlights—September 2023 Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2023-10-10 Frederic I. Preffer
[Color figure can be viewed at wileyonlinelibrary.com] Despite the reality that my entire career has been spent devoted to flow cytometry, it is undeniable to me that the gold standard remains an image of the cell, and when visualized within tissue, the architectural relationships between cells. Thus my keen interest in bringing the Amnis technology into my research laboratory years ago and my current
-
Analytical assay validation for acute myeloid leukemia measurable residual disease assessment by multiparametric flow cytometry Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2023-09-28 Jesse M. Tettero, Naveen Dakappagari, Maaike E. Heidinga, Yvonne Oussoren-Brockhoff, Diana Hanekamp, Anil Pahuja, Kerri Burns, Pavinder Kaur, Zeni Alfonso, Vincent H. J. van der Velden, Jeroen G. te Marvelde, Willemijn Hobo, Jennichjen Slomp, Costa Bachas, Angele Kelder, Kevin Nguyen, Jacqueline Cloos
Measurable residual disease (MRD) assessed by multiparametric flow cytometry (MFC) has gained importance in clinical decision-making for acute myeloid leukemia (AML) patients. However, complying with the recent In Vitro Diagnostic Regulations (IVDR) in Europe and Food and Drug Administration (FDA) guidance in the United States requires rigorous validation prior to their use in investigational clinical
-
Minimal residual disease assessment in B-cell precursor acute lymphoblastic leukemia by semi-automated identification of normal hematopoietic cells: A EuroFlow study Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2023-09-22 Martijn W. C. Verbeek, Beatriz Soriano Rodríguez, Lukasz Sedek, Anna Laqua, Chiara Buracchi, Malicorne Buysse, Michaela Reiterová, Elen Oliveira, Daniela Morf, Sjoerd R. Oude Alink, Susana Barrena, Saskia Kohlscheen, Stefan Nierkens, Mattias Hofmans, Paula Fernandez, Elaine Sobral de Costa, Ester Mejstrikova, Tomasz Szczepanski, Lukasz Slota, Monika Brüggemann, Giuseppe Gaipa, Georgiana Grigore, Jacques
Presence of minimal residual disease (MRD), detected by flow cytometry, is an important prognostic biomarker in the management of B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, data-analysis remains mainly expert-dependent. In this study, we designed and validated an Automated Gating & Identification (AGI) tool for MRD analysis in BCP-ALL patients using the two tubes of the EuroFlow
-
Whole blood no-lyse no-wash micromethod for the quantitative measurement of monocyte HLA-DR Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2023-09-13 Jordi Miatello, Valérie Faivre, Clémence Marais, Mégane Raineau, Didier Payen, Pierre Tissieres
Monocyte (m)HLA-DR expression appears to be a potent marker of immunosuppression in critically ill patients. The persistence of low mHLA-DR expression is associated with an increased risk of nosocomial infections and mortality. To adapt this measurement to pediatric requirements and provide extensive 24/7 access, we have developed a whole blood no-lyse no-wash micromethod (MM) and compared it with
-
Correction to “Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group” Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2023-09-04
van de Loosdrecht, A. A., Kern, W., Porwit, A., Valent, P., Kordasti, S., Cremers, E., Alhan, C., Duetz, C., Dunlop, A., Hobo, W., Preijers, F., Wagner-Ballon, O., Chapuis, N., Fontenay, M., Bettelheim, P., Eidenschink-Brodersen, L., Font, P., Johansson, U., Loken, M. R., … Ireland, R. (2023). Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic
-
Validation of a 12-color flow cytometry assay for acute myeloid leukemia minimal/measurable residual disease detection Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2023-08-22 Sa A. Wang, Jeffrey L. Jorgensen, Shimin Hu, Fuli Jia, Shaoying Li, Sanam Loghavi, Chi Young Ok, Beenu Thakral, Jie Xu, L. Jeffrey Medeiros, Wei Wang
Acute myeloid leukemia (AML) minimal/measurable residual disease (MRD) by multicolor flow cytometry is a complex laboratory developed test (LDT), challenging for implementation. We share our experience in the validation of a 12-color AML MRD flow cytometry assay to meet stringent regulatory requirements.
-
-
An ultra-rapid screening method for acute leukemias. Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2023-08-09 Olof Axler,Filippa Bild,Åsa C M Johansson
-
Clinical significance of end of induction measurable residual disease monitoring in B-cell acute lymphoblastic leukemia: A single center experience Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2023-08-09 Arun Kumar Arunachalam, Sushil Selvarajan, Thenmozhi Mani, Nancy Beryl Janet, Madhavi Maddali, Sharon Anbumalar Lionel, Uday Kulkarni, Anu Korula, Fouzia N. Aboobacker, Aby Abraham, Biju George, Poonkuzhali Balasubramanian, Vikram Mathews
The assessment of measurable residual disease (MRD) has emerged as a powerful prognostic tool for both pediatric and adult acute lymphoblastic leukemia (ALL). This retrospective study aimed to evaluate the prognostic relevance of the end of induction MRD in B-cell acute lymphoblastic leukemia (B ALL) patients. The study included 481 patients who underwent treatment for B ALL between August 2012 and
-
Use of a hybrid intelligence decision tree to identify mature B-cell neoplasms Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2023-08-04 Inès Vergnolle, Theo Ceccomarini, Alban Canali, Jean-Baptiste Rieu, François Vergez
Mature B-cell neoplasms are challenging to diagnose due to their heterogeneity and overlapping clinical and biological features. In this study, we present a new workflow strategy that leverages a large amount of flow cytometry data and an artificial intelligence approach to classify these neoplasms.
-
CD19-negative B-cell precursors in bone marrow: A potential mimicker for CD19-negative B-lymphoblastic leukemia by flow cytometry in patients with anti-CD19 treatment. Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2023-07-27 Weijie Li,Ruth Morgan,Roxanne Nieder,Sahibu Sultan M Habeebu,G Doug Myers
-
Acute leukemia of ambiguous lineage, not otherwise specified with FLT3-ITD mutation and a possible origin in the common lymphoid progenitor. Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2023-05-31 Fernando Martin-Moro,Jose A Garcia-Vela
-
Monocyte HLA-DR expression as an enrollment biomarker in sepsis clinical trials: Evaluation of two sampling tubes and definition of respective clinical thresholds Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2023-05-24 Muzhda Haem Rahimi, Filippo Conti, Jean-Francois Llitjos, Aurore Fleurie, Valérie Cerro, Fabienne Venet, Anne-Claire Lukaszewicz, Guillaume Monneret
CONFLICT OF INTEREST STATEMENT JFL is employed part-time by Hospices Civils de Lyon and bioMérieux. AF is employed by bioMérieux. The authors declare no other conflict of interest.
-
Resolving 31 colors on a standard 3-laser full spectrum flow cytometer for immune monitoring of human blood samples Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2023-05-20 Linda Hammerich, Yaroslava Shevchenko, Jana Knorr, Wiebke Werner, Alix Bruneau, Frank Tacke
Immune monitoring of patients on a single-cell level is becoming increasingly important in various diseases. Due to the often very limited availability of human specimens and our increased understanding of the immune systems there is an increasing demand to analyze as many markers as possible simultaneously in one panel. Full spectrum flow cytometry is emerging as a powerful tool for immune monitoring
-
Automation in flow cytometry: Guidelines and review of systems Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2023-05-13 Ahmad Al-Attar, Kirthi R. Kumar, Dorian Untersee, Marci O'Driscoll, Miguel Francoise S. Ventura, Leo Lin
Automation in flow cytometry has recently advanced from the partial laboratory automation and robotics islets, to more fully integrated systems. This article reviews three manufacturers' newest sample preparation systems: the Beckman CellMek, the Sysmex PS-10, and the BD FACSDuet. These three instruments are capable of performing many of the manual steps in flow cytometry sample processing (pipetting
-
Issue highlights—May 2023 Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2023-05-08 Sa Wang
Sa Wang [Color figure can be viewed at wileyonlinelibrary.com]
-
Extranodal NK/T-cell lymphoma with isolated central nervous system relapse: A defiant disease and the role of flow cytometry in monitoring. Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2023-05-04 Devasis Panda,Amardeep Pathak,Narender Tejwani,Anurag Mehta
-
Summary of validation considerations with real-life examples using both qualitative and semiquantitative flow cytometry assays Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2023-05-03 Katherine A. Devitt, Teri Oldaker, Kalpesh Shah, Andrea Illingworth
In the clinical laboratory, flow cytometry assays are critical to providing diagnostic and prognostic information to the treating clinicians. A validation or verification provides confidence that the assay will yield reliable results that can be trusted to make critical medical decisions. The following performance specifications should be included in a validation for laboratory developed tests as needed:
-
Acquired RUNX1::CBFA2T2 fusion at extramedullary relapse in a patient of PDGFRA rearranged acute myeloid leukemia post allogenic HSCT. Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2023-04-13 Devasis Panda,Amardeep Pathak,Narender Tejwani,Pooja Pandey,Anurag Mehta
-
The impact of Down syndrome-specific non-malignant hematopoietic regeneration in the bone marrow on the detection of leukemic measurable residual disease Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2023-04-04 Fan-Chi Hsu, Chad Hudson, Elisabeth R. Wilson, Laura M. Pardo, Timothy P. Singleton, Dongbin Xu, Barbara K. Zehentner, Johann Hitzler, Jason Berman, Denise A. Wells, Michael R. Loken, Lisa Eidenschink Brodersen
Detection of measurable residual disease detection (MRD) by flow cytometry after the first course of chemotherapy is a standard measure of early response in patients with acute myeloid leukemia (AML). Myeloid leukemia associated with Down Syndrome (ML-DS) is a distinct form of AML. Differences in steady-state and regenerating hematopoiesis between patients with or without DS are not well understood
-
Highly sensitive single tube B-lymphoblastic leukemia/lymphoma minimal/measurable residual disease test robust to surface antigen directed therapy Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2023-03-30 Qi Gao, Ying Liu, Umut Aypar, Jeeyeon Baik, Dory Londono, Xiaotian Sun, Jingping Zhang, Yanming Zhang, Mikhail Roshal
Measurement of minimal/measurable residual disease (MRD) in B-lymphoblastic leukemia/lymphoma (B-ALL) has become a routine clinical evaluation tool and remains the strongest predictor of treatment outcome. In recent years, new targeted anti-CD19 and anti-CD22 antibody-based and cellular therapies have revolutionized the treatment of the high-risk B-ALL. The new treatments raise challenges for diagnostic
-
Correction to “Flow cytometry to detect bone marrow involvement by follicular lymphoma” Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2023-03-16
Aren, M., Marce, S., Jurado, R., Tapia, G., Puigdefabregues, L., Raya, M., Cortes, M., Garcia-Caro, M., Junca, J., Mozas, P., Viñets, E., Cabezon, M., Plensa, E., Miljkovic, M., Sancho, J.-M., Navarro, J.-T., Zamora, L., & Sorigue, M. (2022). Flow cytometry to detect bone marrow involvement by follicular lymphoma. Cytometry Part B: Clinical Cytometry, 102(6), 427–439. https://doi.org/10.1002/cyto.b
-
Comparison of flowcytometry-based scoring system for the diagnosis of early T precursor-acute lymphoblastic leukemia Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2023-03-09 Deepak Marballi Basavaraju, Shruti Mishra, Gaurav Chhabra, Sudarshan Chougule
Early T cell precursor-acute lymphoblastic leukemia (ETP-ALL) is a hematolymphoid malignancy where the blasts demonstrate T cell differentiation markers along with stem cell and myeloid antigen expression. The differential diagnosis of ETP-ALL from non-ETP ALL and mixed phenotype acute leukemia is often challenging due to its overlapping immunophenotypic picture with co-expression of myeloid antigens
-
Addition of formaldehyde releaser imidazolidinyl urea and MOPS buffer to urine samples enables delayed processing for flow cytometric analysis of urinary cells: A simple, two step conservation method of urinary cells for flow cytometry Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2023-03-07 Paul Freund, Christopher M. Skopnik, Diana Metzke, Nina Goerlich, Jan Klocke, Emil Grothgar, Luka Prskalo, Falk Hiepe, Philipp Enghard
Kidney diseases are a major health concern worldwide. Currently there is a large unmet need for novel biomarkers to non-invasively diagnose and monitor kidney diseases. Urinary cells are promising biomarkers and their analysis by flow cytometry has demonstrated its utility in diverse clinical settings. However, up to date this methodology depends on fresh samples, as cellular event counts and the
-
Automated quantification of measurable residual disease in chronic lymphocytic leukemia using an artificial intelligence-assisted workflow Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2023-02-23 Alexandre Bazinet, Alan Wang, Xinmei Li, Fuli Jia, Huan Mo, Wei Wang, Sa A. Wang
Detection of measurable residual disease (MRD) in chronic lymphocytic leukemia (CLL) is an important prognostic marker. The most common CLL MRD method in current use is multiparameter flow cytometry, but availability is limited by the need for expert manual analysis. Automated analysis has the potential to expand access to CLL MRD testing. We evaluated the performance of an artificial intelligence
-
Increased IFN-γ+ and TNF-α+ mucosal-associated invariant T cells in patients with aplastic anemia Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2023-02-13 Xiaohui Chen, Yuping Zhang, Yikai Zhang, Yue Zhang, Shunqing Wang, Zhi Yu, Xiaoen Liu, Guixuan Huang, Lixing Guo, Xueqin Li, Xianfeng Zha, Yangqiu Li, Bo Li
Aplastic anemia (AA) is known as an autoimmune disease in which T cell activation is aberrant. It has been reported that unconventional T cells, mucosal-associated invariant T (MAIT) cells, play an important role in several autoimmune diseases, but it is unclear if they are involved in AA.
-
Alignment, segmentation and neighborhood analysis in cyclic immunohistochemistry data using CASSATT Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2023-02-07 Asa A. Brockman, Rohit Khurana, Todd Bartkowiak, Portia L. Thomas, Shamilene Sivagnanam, Courtney B. Betts, Lisa M. Coussens, Christine M. Lovly, Jonathan M. Irish, Rebecca A. Ihrie
Cyclic immunohistochemistry (cycIHC) uses sequential rounds of colorimetric immunostaining and imaging for quantitative mapping of location and number of cells of interest. Additionally, cycIHC benefits from the speed and simplicity of brightfield microscopy, making the collection of entire tissue sections and slides possible at a trivial cost compared to other high dimensional imaging modalities.
-
Flow cytometric assessment for minimal/measurable residual disease in B lymphoblastic leukemia/lymphoma in the era of immunotherapy Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2023-01-22 Xueyan Chen, Qi Gao, Mikhail Roshal, Sindhu Cherian
Minimal/measurable residual disease (MRD) is the most important independent prognostic factor for patients with B-lymphoblastic leukemia (B-LL). MRD post therapy has been incorporated into risk stratification and clinical management, resulting in substantially improved outcomes in pediatric and adult patients. Currently, MRD in B-ALL is most commonly assessed by multiparametric flow cytometry and molecular
-
Where diagnosis for myelodysplastic neoplasms (MDS) stands today and where it will go: The role of flow cytometry in evaluation of MDS Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2022-12-27 Wei Wang, Joseph D. Khoury
Myelodysplastic neoplasms (MDS) are clonal hematopoietic neoplasms defined by cytopenias and morphologic dysplasia. This definition distinguishes MDS from clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of undetermined significance (CCUS) wherein a patient harbors a somatic mutation involving a myeloid malignancy-associated gene in the absence of cytopenia and, in case of
-
CD19 negative diffuse large B-cell lymphoma presenting in leukemic phase. Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2022-12-21 Thulasi Raman Ramalingam,Ragavi Uthayasuriyan,Vikram Prabhakar,Lakshman Vaidhyanathan
-
Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2022-12-20 Anna Porwit, Marie C. Béné, Carolien Duetz, Sergio Matarraz, Uta Oelschlaegel, Theresia M. Westers, Orianne Wagner-Ballon, Shahram Kordasti, Peter Valent, Frank Preijers, Canan Alhan, Frauke Bellos, Peter Bettelheim, Kate Burbury, Nicolas Chapuis, Eline Cremers, Matteo G. Della Porta, Alan Dunlop, Lisa Eidenschink-Brodersen, Patricia Font, Michaela Fontenay, Willemijn Hobo, Robin Ireland, Ulrika Johansson
Multiparameter flow cytometry (MFC) is one of the essential ancillary methods in bone marrow (BM) investigation of patients with cytopenia and suspected myelodysplastic syndrome (MDS). MFC can also be applied in the follow-up of MDS patients undergoing treatment. This document summarizes recommendations from the International/European Leukemia Net Working Group for Flow Cytometry in Myelodysplastic
-
Human leukocyte antigen-B27 typing by flow cytometry: Comparison of three CE-IVD methods Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2022-11-30 Louis Waeckel, Anne Kennel, Anne-Emmanuelle Berger, Claude Lambert
The human leukocyte antigen B27 (HLA-B27), associated with chronic inflammatory diseases is thus widely performed for diagnostic purposes. Genotyping by molecular biology is the current gold standard for HLA-B27 typing, but cheaper and faster flow cytometry methods have been developed.
-
Optimization of monocyte gating to quantify monocyte subsets for the diagnosis of chronic myelomonocytic leukemia Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2022-11-30 Rebeca Jurado, Maria Huguet, Blanca Xicoy, Marta Cabezon, Ari Jimenez-Ponce, David Quintela, Cristina De La Fuente, Minerva Raya, Esther Vinets, Jordi Junca, Joaquim Julià-Torras, Lurdes Zamora, Albert Oriol, Jose-Tomas Navarro, Xavier Calvo, Marc Sorigue
The presence of >94% classical monocytes (MO1, CD14++/CD16-) in peripheral blood (PB) has an excellent performance for the diagnosis of chronic myelomonocytic leukemia (CMML). However, the monocyte gating strategy is not well defined. The objective of the study was to compare monocyte gating strategies and propose an optimal one.
-
The patterns and diagnostic significance of the lack of surface immunoglobulin light chain on mature B cells in clinical samples for lymphoma workup Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2022-11-30 Sara L. Huang, Thomas Fennell, Xia Chen, James Z. Huang
Surface immunoglobulin (sIg) light chains are not always detected on mature B cells. This may present as a challenge for clonality determination in clinical flow cytometry.
-
Circulating CD22+/CD19−/CD24− progenitors and CD22+/CD19+/CD24− mature B cells: Diagnostic pitfalls for minimal residual disease detection in B-lymphoblastic leukemia Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2022-11-26 Ting Zhou, Jeremiah Karrs, Truc Ho, Alyssa Doverte, James N. Kochenderfer, Nirali N. Shah, Constance M. Yuan, Hao-Wei Wang
Multiparametric flow cytometry (MFC) has become a powerful tool in minimal residual disease (MRD) detection in B-lymphoblastic leukemia/lymphoma (B-ALL). In the setting of targeted immunotherapy, B-ALL MRD detection often relies on alterative gating strategies, such as the utilization of CD22 and CD24. It is important to depict the full diversity of normal cell populations included in the alternative
-
Multicenter prospective evaluation of diagnostic potential of flow cytometric aberrancies in myelodysplastic syndromes by the ELN iMDS flow working group Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2022-11-23 Wolfgang Kern, Theresia M. Westers, Frauke Bellos, Marie Christine Bene, Peter Bettelheim, Lisa Eidenschink Brodersen, Kate Burbury, Sung-Chao Chu, Matthew Cullen, Matteo Della Porta, Alan Stewart Dunlop, Ulrika Johansson, Sergio Matarraz, Uta Oelschlaegel, Kiyoyuki Ogata, Anna Porwit, Frank Preijers, Katherina Psarra, Leonie Saft, Dolores Subirá, Elisabeth Weiß, Vincent H. J. van der Velden, Arjan
Myelodysplastic syndromes (MDS) represent a diagnostic challenge. This prospective multicenter study was conducted to evaluate pre-defined flow cytometric markers in the diagnostic work-up of MDS and chronic myelomonocytic leukemia (CMML).
-
Flow cytometry in the diagnosis of myelodysplastic syndromes Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2022-11-21 Wolfgang Kern, Arjan van de Loosdrecht
In hematologic neoplasms, the identification of recurrent disease-associated phenotypic features in general is followed after a prolonged period by the identification of disease-associated and even disease-defining genetic changes based on which specific treatment will be developed. As an example, for chronic myelogenous leukemia (CML) this has taken one and a half century from the first publication
-
Issue highlights—November 2022 Cytom. Part B Clin. Cytom. (IF 3.4) Pub Date : 2022-11-18 János Kappelmayer
János Kappelmayer [Color figure can be viewed at wileyonlinelibrary.com]